Cargando…

Functional cRGD-Conjugated Polymer Prodrug for Targeted Drug Delivery to Liver Cancer Cells

[Image: see text] To overcome the limitation of conventional nanodrugs in tumor targeting efficiency, coupling targeting ligands to polymeric nanoparticles can enhance the specific binding of nanodrugs to tumors. Cyclo(Arg-Gly-Asp-d-Phe-Lys) (abbreviated as c(RGDfK)) peptide has been widely adopted...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ru, Zhang, Mingzu, He, Jinlin, Liu, Jian, Sun, Xingwei, Ni, Peihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219052/
https://www.ncbi.nlm.nih.gov/pubmed/35755339
http://dx.doi.org/10.1021/acsomega.2c02683
_version_ 1784732023828512768
author Zhou, Ru
Zhang, Mingzu
He, Jinlin
Liu, Jian
Sun, Xingwei
Ni, Peihong
author_facet Zhou, Ru
Zhang, Mingzu
He, Jinlin
Liu, Jian
Sun, Xingwei
Ni, Peihong
author_sort Zhou, Ru
collection PubMed
description [Image: see text] To overcome the limitation of conventional nanodrugs in tumor targeting efficiency, coupling targeting ligands to polymeric nanoparticles can enhance the specific binding of nanodrugs to tumors. Cyclo(Arg-Gly-Asp-d-Phe-Lys) (abbreviated as c(RGDfK)) peptide has been widely adopted due to its high affinity to the tumor marker α(v)β(3) integrin receptor. In this study, we develop a cRGD peptide-conjugated camptothecin (CPT) prodrug, which enables self-assembly of nanoparticles for precise targeting and enrichment in tumor tissue. We first synthesized a camptothecin derivative (CPT-ss-N(3)) with a reduction-sensitive bond and simultaneously modified PEG to obtain cRGD-PEG-N(3). After ring-opening polymerization of the 2-(but-3-yn-1-yolxy)-2-oxo-1,3,2-dioxaphospholane (BYP), an amphiphilic polymeric prodrug, referred to as cRGD-PEG-g-(PBYP-ss-CPT), was obtained via copper-catalyzed azide–alkyne cycloaddition (CuAAC) reaction. The self-assembly in buffer solution of the cRGD-functional prodrug was studied through DLS and TEM. The in vitro drug release behavior of cRGD-PEG-g-(PBYP-ss-CPT) nanoparticles was investigated. The results show that the nanoparticles are reduction-responsive and the bonded CPT can be released. Endocytosis and MTT assays demonstrate that the cRGD-conjugated prodrug has better affinity for tumor cells, accumulates more intracellularly, and is therefore, more effective. The in vivo drug metabolism studies show that nanoparticles greatly prolong the retention time in circulation. By monitoring drug distribution in tumor and in various tissues, we find that free CPT can be rapidly metabolized, resulting in low accumulation in all tissues. However, cRGD-PEG-g-(PBYP-ss-CPT) nanoparticles accumulate in tumor tissues in higher amounts than PEG-g-(PBYP-ss-CPT) nanoparticles, except for the inevitable capture by the liver. This indicates that the nanomedicine with cRGD has a certain targeting property, which can improve drug delivery efficiency.
format Online
Article
Text
id pubmed-9219052
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-92190522022-06-24 Functional cRGD-Conjugated Polymer Prodrug for Targeted Drug Delivery to Liver Cancer Cells Zhou, Ru Zhang, Mingzu He, Jinlin Liu, Jian Sun, Xingwei Ni, Peihong ACS Omega [Image: see text] To overcome the limitation of conventional nanodrugs in tumor targeting efficiency, coupling targeting ligands to polymeric nanoparticles can enhance the specific binding of nanodrugs to tumors. Cyclo(Arg-Gly-Asp-d-Phe-Lys) (abbreviated as c(RGDfK)) peptide has been widely adopted due to its high affinity to the tumor marker α(v)β(3) integrin receptor. In this study, we develop a cRGD peptide-conjugated camptothecin (CPT) prodrug, which enables self-assembly of nanoparticles for precise targeting and enrichment in tumor tissue. We first synthesized a camptothecin derivative (CPT-ss-N(3)) with a reduction-sensitive bond and simultaneously modified PEG to obtain cRGD-PEG-N(3). After ring-opening polymerization of the 2-(but-3-yn-1-yolxy)-2-oxo-1,3,2-dioxaphospholane (BYP), an amphiphilic polymeric prodrug, referred to as cRGD-PEG-g-(PBYP-ss-CPT), was obtained via copper-catalyzed azide–alkyne cycloaddition (CuAAC) reaction. The self-assembly in buffer solution of the cRGD-functional prodrug was studied through DLS and TEM. The in vitro drug release behavior of cRGD-PEG-g-(PBYP-ss-CPT) nanoparticles was investigated. The results show that the nanoparticles are reduction-responsive and the bonded CPT can be released. Endocytosis and MTT assays demonstrate that the cRGD-conjugated prodrug has better affinity for tumor cells, accumulates more intracellularly, and is therefore, more effective. The in vivo drug metabolism studies show that nanoparticles greatly prolong the retention time in circulation. By monitoring drug distribution in tumor and in various tissues, we find that free CPT can be rapidly metabolized, resulting in low accumulation in all tissues. However, cRGD-PEG-g-(PBYP-ss-CPT) nanoparticles accumulate in tumor tissues in higher amounts than PEG-g-(PBYP-ss-CPT) nanoparticles, except for the inevitable capture by the liver. This indicates that the nanomedicine with cRGD has a certain targeting property, which can improve drug delivery efficiency. American Chemical Society 2022-06-07 /pmc/articles/PMC9219052/ /pubmed/35755339 http://dx.doi.org/10.1021/acsomega.2c02683 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Zhou, Ru
Zhang, Mingzu
He, Jinlin
Liu, Jian
Sun, Xingwei
Ni, Peihong
Functional cRGD-Conjugated Polymer Prodrug for Targeted Drug Delivery to Liver Cancer Cells
title Functional cRGD-Conjugated Polymer Prodrug for Targeted Drug Delivery to Liver Cancer Cells
title_full Functional cRGD-Conjugated Polymer Prodrug for Targeted Drug Delivery to Liver Cancer Cells
title_fullStr Functional cRGD-Conjugated Polymer Prodrug for Targeted Drug Delivery to Liver Cancer Cells
title_full_unstemmed Functional cRGD-Conjugated Polymer Prodrug for Targeted Drug Delivery to Liver Cancer Cells
title_short Functional cRGD-Conjugated Polymer Prodrug for Targeted Drug Delivery to Liver Cancer Cells
title_sort functional crgd-conjugated polymer prodrug for targeted drug delivery to liver cancer cells
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219052/
https://www.ncbi.nlm.nih.gov/pubmed/35755339
http://dx.doi.org/10.1021/acsomega.2c02683
work_keys_str_mv AT zhouru functionalcrgdconjugatedpolymerprodrugfortargeteddrugdeliverytolivercancercells
AT zhangmingzu functionalcrgdconjugatedpolymerprodrugfortargeteddrugdeliverytolivercancercells
AT hejinlin functionalcrgdconjugatedpolymerprodrugfortargeteddrugdeliverytolivercancercells
AT liujian functionalcrgdconjugatedpolymerprodrugfortargeteddrugdeliverytolivercancercells
AT sunxingwei functionalcrgdconjugatedpolymerprodrugfortargeteddrugdeliverytolivercancercells
AT nipeihong functionalcrgdconjugatedpolymerprodrugfortargeteddrugdeliverytolivercancercells